MRC1 and Lynch syndrome: The FCC clinicians may feel more confident in providing risk management advice to BRCA1/2 pathogenic variant carriers compared to those with variants in MMR genes; if so, this may be the result of a greater volume of research being available regarding the efficacy of risk management in BRCA1/2 pathogenic variant carriers and/or FCC staff being more experienced in providing advice to such carriers, given that most patients attending FCCs are from hereditary breast ovarian cancer families rather than families with Lynch syndrome [22].